Eisai Pharmaceuticals, one of Japan’s biggest drugs-related research and development companies, has opened its regional offices at Dubai Healthcare City as part of plans to offer innovative treatment in oncology and neurology to patients in the MENA region.
Eisai is set to introduce a revolutionary treatment for breast cancer, the third leading cause of death in the UAE according to a study conducted by the Dubai-based Centre for Arab Genomic Studies.
Ayman El Deeb, the new EMEA regional director for Eisai, said: “Eisai’s entry into the Middle East and Africa region enforces our wider plan of increasing access to medicines based on a strategy of affordability, availability, adoption and architecture.
“The company’s expansion is an opportunity to make our currently marketed and pipeline products available, bringing state-of-the-art therapies to patients in the region,” he added in comments published by state news agency WAM.
Dr Ayesha Abdulla, managing director of Dubai Healthcare City, added: “The presence of Eisai, the first Japanese pharmaceutical company in Dubai Healthcare City, complements our commitment to hosting specialised healthcare providers and pharmaceutical companies at the free zone.
“Eisai will also help us translate our endeavour to offer unique services and products to our growing patient base.
“Oncology and neurology are our key focus areas at DHCC and we look towards Eisai Pharmaceuticals to help us offer quality treatment and innovative solutions.”
According to recent pharmaceutical data, drug consumption in the MENA region accounts for about 1.5 percent of the global total totalling about $9bn.
The UAE is second in the region in terms of capital invested in the pharmaceutical sector.
A recent RNCOS, an industry research solution company, report outlined that the pharmaceutical market in the region is expected to grow at a compound annual growth rate (CAGR) of around 9.5 percent during 2011-2013.
Follow us on
